Celsus Therapeutics Priced, Nasdaq: CLTX
Clinical-stage biotech developing novel anti-inflammatory synthetic drugs.
Industry: Other
First Day Return: n/a
Industry: Other
CLTX
Clinical-stage biotech developing novel anti-inflammatory synthetic drugs.
| IPO Data | |
|---|---|
| IPO File Date | 12/12/2013 |
| Offer Price | $6.00 |
| Price Range $7.10 - $7.10 | |
| Offer Shares (mm) | 1.3 |
| Deal Size ($mm) | $8 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 01/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $8 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | London, United Kingdom |
| Founded | 2005 |
| Employees at IPO | 2 |
| Website http://www.celsustx.com | |
IPO News for Celsus Therapeutics
Celsus Therapeutics (CLTX) Performance
